ID

44718

Beschreibung

The purpose of this Phase II study is to determine if AZD4877, an experimental drug that is a novel anti-mitotic agent (Eg5 or Kinesin Spindle Protein inhibitor that interferes with tumor cell division leading to tumor growth), can reduce tumor sizes in patients with bladder cancer see http://clinicaltrials.gov/ct2/show/study/NCT00661609

Link

http://clinicaltrials.gov/ct2/show/study/NCT00661609

Stichworte

  1. 21.11.11 21.11.11 -
  2. 27.03.14 27.03.14 - Martin Dugas
  3. 17.09.21 17.09.21 -
  4. 27.09.21 27.09.21 - Sarah Riepenhausen
Rechteinhaber

AstraZeneca

Hochgeladen am

27. September 2021

DOI

Für eine Beantragung loggen Sie sich ein.

Lizenz

Creative Commons BY 4.0

Modell Kommentare :

Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.

Itemgroup Kommentare für :

Item Kommentare für :

Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.

A Phase II Study of AZD4877 (a Novel Anti-mitotic DRKS00004052

Eligibility Bladder Cancer NCT00661609

Inclusion criteria
Beschreibung

Inclusion criteria

Alias
UMLS CUI [1]
C1512693
Confirmed urothelial cancer (cancer of the bladder, renal pelvis, ureter, or urethra).
Beschreibung

Urothelial cancer

Datentyp

boolean

Alias
UMLS CUI [1]
C1519840
Tumor, Node, Metastasis (TNM) Stage IV urothelial cancer that can not be helped by curative surgery and/or curative radiotherapy
Beschreibung

Stage IV

Datentyp

boolean

Alias
UMLS CUI-1
C0441772
Must have had a maximum of 2 prior chemotherapeutic regimens, one for unremovable and/or metastasized disease, and the other in the adjuvant or neo-adjuvant setting.
Beschreibung

Prior chemotherapy

Datentyp

boolean

Alias
UMLS CUI-1
C1514457
Ambulatory and capable of all selfcare more than 50% of waking hours
Beschreibung

Selfcare

Datentyp

boolean

Alias
UMLS CUI-1
C0036592
Exclusion criteria
Beschreibung

Exclusion criteria

Alias
UMLS CUI [1]
C0680251
Prior treatment with investigational or standard anti-cancer agents, including radiotherapy, within 4 weeks prior to first dose of study medication; 6 weeks if prior systemic mitomycin, nitrosourea, or suramin.
Beschreibung

Prior treatment

Datentyp

boolean

Alias
UMLS CUI-1
C1514463
Inadequate bone marrow reserve
Beschreibung

Bone marrow

Datentyp

boolean

Alias
UMLS CUI-1
C0005953
Inadequate liver function in the presence of liver metastases
Beschreibung

Liver function

Datentyp

boolean

Alias
UMLS CUI
C0232744
Impaired renal function
Beschreibung

Renal function

Datentyp

boolean

Alias
UMLS CUI
C1565489

Ähnliche Modelle

Eligibility Bladder Cancer NCT00661609

Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Item Group
Inclusion criteria
C1512693 (UMLS CUI [1])
Urothelial cancer
Item
Confirmed urothelial cancer (cancer of the bladder, renal pelvis, ureter, or urethra).
boolean
C1519840 (UMLS CUI [1])
Stage IV
Item
Tumor, Node, Metastasis (TNM) Stage IV urothelial cancer that can not be helped by curative surgery and/or curative radiotherapy
boolean
C0441772 (UMLS CUI-1)
Prior chemotherapy
Item
Must have had a maximum of 2 prior chemotherapeutic regimens, one for unremovable and/or metastasized disease, and the other in the adjuvant or neo-adjuvant setting.
boolean
C1514457 (UMLS CUI-1)
Selfcare
Item
Ambulatory and capable of all selfcare more than 50% of waking hours
boolean
C0036592 (UMLS CUI-1)
Item Group
Exclusion criteria
C0680251 (UMLS CUI [1])
Prior treatment
Item
Prior treatment with investigational or standard anti-cancer agents, including radiotherapy, within 4 weeks prior to first dose of study medication; 6 weeks if prior systemic mitomycin, nitrosourea, or suramin.
boolean
C1514463 (UMLS CUI-1)
Bone marrow
Item
Inadequate bone marrow reserve
boolean
C0005953 (UMLS CUI-1)
Liver function
Item
Inadequate liver function in the presence of liver metastases
boolean
C0232744 (UMLS CUI)
Renal function
Item
Impaired renal function
boolean
C1565489 (UMLS CUI)

Benutzen Sie dieses Formular für Rückmeldungen, Fragen und Verbesserungsvorschläge.

Mit * gekennzeichnete Felder sind notwendig.

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video